VA Initiates MDMA-Assisted Therapy Trial for PTSD and Alcohol Use Disorder
The VA has launched a clinical trial for MDMA-assisted therapy, targeting PTSD and alcohol use disorder among Veterans. This initiative, in coordination with the FDA, presents procurement opportunities related to clinical research and mental health services.
Key Signals
- VA trial targets PTSD with MDMA-assisted therapy
- Approximately 80 Veterans to participate in clinical trial
- FDA collaboration may streamline approval for new therapies
"We need an all-of-the-above strategy when it comes to improving mental health treatments, and under President Trump, thats exactly what VA is working to deliver."
The U.S. Department of Veterans Affairs (VA) took a significant step towards enhancing mental health treatments for Veterans by launching a randomized controlled clinical trial aimed at evaluating the efficacy of methylenedioxymethamphetamine (MDMA)-assisted therapy. Announced on May 26, 2026, this trial seeks to treat Post-Traumatic Stress Disorder (PTSD) and alcohol use disorder among approximately 80 Veterans. The trial sites are strategically located at the VA Providence Healthcare System in Rhode Island and the VA Connecticut Healthcare System in West Haven, Connecticut.
This trial represents a critical development not only in mental health care but also in the way the VA is engaging with innovative treatment models for severe mental health issues. By collaborating with the U.S. Food and Drug Administration (FDA), the VA is not only aiming for enhanced and expedited therapeutic applications but is also setting a precedent for the use of psychedelic-assisted therapies in clinical settings. These efforts align with recent executive orders aimed at accelerating the development of medical treatments for serious mental illnesses, suggesting a broader commitment to innovative approaches in federal healthcare.
The implications for procurement professionals are significant. As the VA expands its clinical trial capabilities and explores new treatment avenues, contracting opportunities will likely emerge within the federal healthcare sector. Contractors with specialized expertise in clinical research, pharmaceutical supplies, and mental health services should keep a close watch on this trial. Engaging with the VA at this juncture could lead to involvement in future procurements as the VA continues to explore and validate new therapeutic modalities.
As part of its ongoing commitment to improving mental health treatment, the VA has already been investing in various clinical trials focusing on psychedelics. The inclusion of MDMA in this context not only highlights the evolving landscape of mental health therapies but also underscores the VA’s intent to follow scientifically-supported pathways in addressing complex conditions affecting Veterans.
Agencies
- U.S. Department of Veterans Affairs
- U.S. Food and Drug Administration